Spectratyping peak distributions
Source of sample . | Day after chemotherapy . | T lymphocytes assayed . | Total peaks, n . | Driven peaks, n . | Percentage of driven peaks . |
---|---|---|---|---|---|
Control 1 | N/A | Unsorted | 164 | 3 | 1.83 |
Control 2 | N/A | Unsorted | 175 | 5 | 2.86 |
Patient 5 | 88 | Unsorted | 172 | 28 | 16.3 |
Patient 17 | 31 | Unsorted | 157 | 32 | 20.4 |
Patient 20 | 21 | Unsorted | 144 | 40 | 27.8 |
Patient 5 | 32 | Regulatory T cells | 7 | 6 | 85.7 |
Patient 5 | 88 | Regulatory T cells | 61 | 42 | 68.9 |
Patient 8 | 23 | Regulatory T cells | 13 | 13 | 100 |
Patient 8 | 95 | Regulatory T cells | 1 | 1 | 100 |
Patient 9 | 30 | Regulatory T cells | 95 | 32 | 33.7 |
Patient 11 | 22 | Regulatory T cells | 49 | 29 | 59.2 |
Patient 16 | 23 | Regulatory T cells | 1 | 1 | 100 |
Patient 17 | 31 | Regulatory T cells | 100 | 39 | 39.0 |
Patient 20 | 21 | Regulatory T cells | 45 | 34 | 75.6 |
Patient 20 | 30 | Regulatory T cells | 2 | 2 | 100 |
Source of sample . | Day after chemotherapy . | T lymphocytes assayed . | Total peaks, n . | Driven peaks, n . | Percentage of driven peaks . |
---|---|---|---|---|---|
Control 1 | N/A | Unsorted | 164 | 3 | 1.83 |
Control 2 | N/A | Unsorted | 175 | 5 | 2.86 |
Patient 5 | 88 | Unsorted | 172 | 28 | 16.3 |
Patient 17 | 31 | Unsorted | 157 | 32 | 20.4 |
Patient 20 | 21 | Unsorted | 144 | 40 | 27.8 |
Patient 5 | 32 | Regulatory T cells | 7 | 6 | 85.7 |
Patient 5 | 88 | Regulatory T cells | 61 | 42 | 68.9 |
Patient 8 | 23 | Regulatory T cells | 13 | 13 | 100 |
Patient 8 | 95 | Regulatory T cells | 1 | 1 | 100 |
Patient 9 | 30 | Regulatory T cells | 95 | 32 | 33.7 |
Patient 11 | 22 | Regulatory T cells | 49 | 29 | 59.2 |
Patient 16 | 23 | Regulatory T cells | 1 | 1 | 100 |
Patient 17 | 31 | Regulatory T cells | 100 | 39 | 39.0 |
Patient 20 | 21 | Regulatory T cells | 45 | 34 | 75.6 |
Patient 20 | 30 | Regulatory T cells | 2 | 2 | 100 |